A new trading day began on Monday, with Zymeworks BC Inc (NASDAQ: ZYME) stock price down -4.75% from the previous day of trading, before settling in for the closing price of $10.95. ZYME’s price has ranged from $7.97 to $17.70 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 273.04%. Meanwhile, its annual earnings per share averaged -3.28%. With a float of $67.30 million, this company’s outstanding shares have now reached $68.96 million.
Let’s determine the extent of company efficiency that accounts for 286 employees. In terms of profitability, gross margin is 50.29%, operating margin of -157.03%, and the pretax margin is -152.82%.
Zymeworks BC Inc (ZYME) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Zymeworks BC Inc is 4.07%, while institutional ownership is 97.65%. The most recent insider transaction that took place on Apr 04 ’25, was worth 2,193,800. In this transaction Director of this company bought 196,438 shares at a rate of $11.17, taking the stock ownership to the 17,699,774 shares. Before that another transaction happened on Apr 03 ’25, when Company’s Director bought 120,770 for $11.84, making the entire transaction worth $1,430,170. This insider now owns 17,503,336 shares in total.
Zymeworks BC Inc (ZYME) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.47 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -3.28% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.14% during the next five years compared to 15.81% growth over the previous five years of trading.
Zymeworks BC Inc (NASDAQ: ZYME) Trading Performance Indicators
Here are Zymeworks BC Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.40. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.59.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.62, a number that is poised to hit -0.68 in the next quarter and is forecasted to reach -0.93 in one year’s time.
Technical Analysis of Zymeworks BC Inc (ZYME)
Looking closely at Zymeworks BC Inc (NASDAQ: ZYME), its last 5-days average volume was 0.95 million, which is a jump from its year-to-date volume of 0.56 million. As of the previous 9 days, the stock’s Stochastic %D was 17.78%. Additionally, its Average True Range was 0.73.
During the past 100 days, Zymeworks BC Inc’s (ZYME) raw stochastic average was set at 9.01%, which indicates a significant decrease from 20.20% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 46.80% in the past 14 days, which was lower than the 54.73% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $13.22, while its 200-day Moving Average is $12.63. However, in the short run, Zymeworks BC Inc’s stock first resistance to watch stands at $10.88. Second resistance stands at $11.33. The third major resistance level sits at $11.91. If the price goes on to break the first support level at $9.85, it is likely to go to the next support level at $9.26. Should the price break the second support level, the third support level stands at $8.81.
Zymeworks BC Inc (NASDAQ: ZYME) Key Stats
With a market capitalization of 731.64 million, the company has a total of 69,577K Shares Outstanding. Currently, annual sales are 76,300 K while annual income is -122,700 K. The company’s previous quarter sales were 31,030 K while its latest quarter income was -23,510 K.
